Drug data last refreshed 12h ago · AI intelligence enriched 18h ago
LIBRIUM is an injectable medication approved in 1961 by Bausch + Lomb. The specific indication and mechanism of action are not documented in available data. This is a legacy small molecule product with a long commercial history.
Product approaching loss of exclusivity with moderate competitive pressure (30/100), suggesting significant commercial restructuring ahead and potential team downsizing.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Phage-based Control and Limitation of Pathobionts for Microbiome Equilibrium and Resilience
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium - Maintenance
Regulated Stimulation for Optimized Network Activity and Therapeutic Equilibrium
Carbetocin Trial: Carbetocin Appropriate Rate Better Equilibrium Between Tonus (TOnus) and CIrculatioN
Worked on LIBRIUM at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LIBRIUM currently shows zero linked job openings, reflecting its mature, legacy status. Working on this product offers limited growth trajectory and declining hiring momentum as the brand approaches loss of exclusivity.